Novartis Projects 5% Annual Sales Growth In CC Through 2031, Sustained Growth Over Long Term
(RTTNews) - Swiss drug major Novartis AG (NVS, NOVN.SW) Thursday announced its mid-term guidance to 2026-2031, with net sales expected to grow 5 percent at constant currency CAGR. The firm added that core operating income margin is on track to return to more than 40 percent by 20
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.